$478 Million is the total value of Samsara BioCapital, LLC's 40 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 12.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | CARGO THERAPEUTICS INC | $72,505,613 | -21.2% | 4,415,689 | +7.1% | 15.18% | +6.6% | |
| MINERALYS THERAPEUTICS INC | $59,376,517 | -9.4% | 5,074,916 | 0.0% | 12.43% | +22.6% | ||
| SRRK | SCHOLAR ROCK HLDG CORP | $56,549,113 | -53.1% | 6,788,609 | 0.0% | 11.84% | -36.6% | |
| NEUROGENE INC | $46,134,878 | -28.5% | 1,267,790 | 0.0% | 9.66% | -3.3% | ||
| ARCELLX INC | $25,036,447 | -20.6% | 453,641 | 0.0% | 5.24% | +7.4% | ||
| New | ELIEM THERAPEUTICS INC | $23,188,504 | – | 3,261,393 | +100.0% | 4.85% | – | |
| NKTX | NKARTA INC | $22,269,087 | -45.3% | 3,768,035 | 0.0% | 4.66% | -26.0% | |
| LENZ THERAPEUTICS INC | $20,894,498 | -22.6% | 1,208,473 | 0.0% | 4.37% | +4.7% | ||
| New | AVADEL PHARMACEUTICALS PLC | $13,603,430 | – | 967,527 | +100.0% | 2.85% | – | |
| JASPER THERAPEUTICS INC | $11,917,500 | -22.7% | 525,000 | 0.0% | 2.49% | +4.6% | ||
| HILLEVAX INC | $11,557,502 | -13.0% | 799,274 | 0.0% | 2.42% | +17.7% | ||
| ABIVAX SAsponsored ads | $11,237,000 | -7.6% | 850,000 | 0.0% | 2.35% | +25.1% | ||
| ACELYRIN INC | $11,126,527 | -34.7% | 2,523,022 | 0.0% | 2.33% | -11.6% | ||
| New | CONTINEUM THERAPEUTICS INCcl a | $10,369,067 | – | 588,817 | +100.0% | 2.17% | – | |
| SYROS PHARMACEUTICALS INC | $9,217,963 | -3.6% | 1,786,427 | 0.0% | 1.93% | +30.4% | ||
| Sell | ZYMEWORKS INC | $8,510,000 | -44.6% | 1,000,000 | -31.5% | 1.78% | -25.0% | |
| RYTM | RHYTHM PHARMACEUTICALS INC | $7,088,886 | -5.2% | 172,647 | 0.0% | 1.48% | +28.3% | |
| INZY | INOZYME PHARMA INC | $6,968,750 | -41.8% | 1,562,500 | 0.0% | 1.46% | -21.2% | |
| STRO | Buy | SUTRO BIOPHARMA INC | $6,436,665 | -32.0% | 2,196,814 | +31.1% | 1.35% | -8.1% |
| GOSS | GOSSAMER BIO INC | $5,522,758 | -23.7% | 6,130,268 | 0.0% | 1.16% | +3.3% | |
| TANGO THERAPEUTICS INC | $5,405,400 | +8.1% | 630,000 | 0.0% | 1.13% | +46.1% | ||
| VRNA | VERONA PHARMA PLCsponsored ads | $5,024,850 | -10.1% | 347,500 | 0.0% | 1.05% | +21.6% | |
| Buy | LEAP THERAPEUTICS INC | $4,787,010 | +168.9% | 2,442,352 | +264.9% | 1.00% | +264.4% | |
| IO BIOTECH INC | $4,258,818 | -32.4% | 3,640,015 | 0.0% | 0.89% | -8.5% | ||
| VTV THERAPEUTICS INCcl a new | $3,651,805 | -24.9% | 206,784 | 0.0% | 0.76% | +1.5% | ||
| PRIME MEDICINE INC | $2,777,163 | -26.6% | 540,304 | 0.0% | 0.58% | -0.7% | ||
| DAWN | DAY ONE BIOPHARMACEUTICALS I | $2,706,737 | -16.6% | 196,425 | 0.0% | 0.57% | +12.9% | |
| IMTX | Sell | IMMATICS N.V | $2,300,760 | -44.7% | 198,000 | -50.0% | 0.48% | -25.2% |
| JANX | Sell | JANUX THERAPEUTICS INC | $1,887,228 | -72.2% | 45,052 | -75.0% | 0.40% | -62.4% |
| TERN | TERNS PHARMACEUTICALS INC | $1,377,990 | +3.8% | 202,348 | 0.0% | 0.29% | +40.5% | |
| IGMS | IGM BIOSCIENCES INC | $1,062,542 | -28.8% | 154,664 | 0.0% | 0.22% | -3.9% | |
| BOLT | BOLT BIOTHERAPEUTICS INC | $786,865 | -46.4% | 1,049,153 | 0.0% | 0.16% | -27.3% | |
| LYRA | LYRA THERAPEUTICS INC | $769,298 | -95.6% | 2,780,261 | 0.0% | 0.16% | -94.0% | |
| ACRS | ACLARIS THERAPEUTICS INC | $765,788 | -11.3% | 696,171 | 0.0% | 0.16% | +19.4% | |
| VIRX | VIRACTA THERAPEUTICS INC | $374,995 | -46.7% | 689,709 | 0.0% | 0.08% | -28.4% | |
| ALLK | ALLAKOS INC | $172,089 | -20.6% | 172,089 | 0.0% | 0.04% | +5.9% | |
| KRON | KRONOS BIO INC | $96,882 | -4.6% | 78,131 | 0.0% | 0.02% | +25.0% | |
| ALVR | ALLOVIR INC | $59,554 | -4.2% | 82,336 | 0.0% | 0.01% | +20.0% | |
| NUVBWS | NUVATION BIO INC*w exp 07/07/202 | $21,333 | -47.1% | 133,333 | 0.0% | 0.00% | -33.3% | |
| SURROZEN INC*w exp 08/01/203 | $1,660 | -45.0% | 99,999 | 0.0% | 0.00% | – | ||
| Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -291,666 | -100.0% | -0.64% | – | |
| AVDL | Exit | AVADEL PHARMACEUTICALS PLCsponsored adr | $0 | – | -967,527 | -100.0% | -2.53% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALLAKOS INC | 23 | Q2 2024 | 23.0% |
| SUTRO BIOPHARMA INC | 23 | Q2 2024 | 10.1% |
| Intercept Pharmaceuticals Inc | 20 | Q3 2023 | 24.0% |
| ACLARIS THERAPEUTICS INC | 18 | Q2 2024 | 4.8% |
| RHYTHM PHARMACEUTICALS INC | 18 | Q2 2024 | 2.4% |
| VERONA PHARMA PLC | 17 | Q2 2024 | 3.9% |
| NKARTA INC | 16 | Q2 2024 | 17.1% |
| SYROS PHARMACEUTICALS INC | 16 | Q3 2022 | 11.6% |
| ATRECA INC | 16 | Q1 2023 | 7.4% |
| ALLOVIR INC | 16 | Q2 2024 | 0.7% |
View Samsara BioCapital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-15 |
| 13F-HR | 2023-02-14 |
View Samsara BioCapital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.